ModifiedUnitedHealthcarePolicy CS086KY.11

Occipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for Kentucky Only)

This policy governs coverage and medical necessity criteria for occipital nerve injections, blocks, neurostimulation, surgical procedures, and ablation related to occipital neuralgia and headache for UnitedHealthcare members in Kentucky.

Policy Summary

PayerUnitedHealthcare

PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for Kentucky Only)

Policy CodePolicy CS086KY.11

Change TypeMaterial revisions and code removal

Effective DateNov 1, 2024

Next Review Date

Key ActionUse InterQual CP: Procedures, Neuroablation, Percutaneous to determine medical necessity for occipital nerve ablation in severe cancer-related head and neck pain.

SourceLink

POLICY UPDATE CHANGES

Removed language indicating occipital nerve ablation (destruction by neurolytic agent) is proven and medically necessary for treating pain due to malignancy involving the head and neck.

Updated instruction to refer to the InterQual® CP: Procedures, Neuroablation, Percutaneous for medical necessity clinical coverage criteria for occipital nerve ablation for severe cancer pain due to malignancy involving the head and neck.

Removed HCPCS code K1023 from applicable codes.

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

Kentucky-onlystate-specific application

InterQualInterQual referenced

K1023

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

MultipleUnproven/NMN treatments

85%Reported ablation success

Coverage Criteria

Ablation for cancer-related head and neck pain

Covered when ALL of the following are met

Occipital nerve ablation for cancer pain: Occipital nerve ablation for severe cancer pain due to malignancy involving the head and neck is covered when medical necessity is established per InterQual® CP: Procedures, Neuroablation, Percutaneous.see InterQual®

InterQual referenced in policy; refer to plan/federal/state requirements when applying InterQual; prior policy language asserting neurolytic ablation as proven for malignant head/neck pain was removed.

Not medically necessary / Unproven treatments for occipital neuralgia and headaches

Not medically necessary for occipital neuralgia or headaches

Unproven interventions: The following are unproven and not medically necessary for diagnosing and/or treating occipital neuralgia or headaches (including migraine and cervicogenic headache): injection of local anesthetics and/or steroids used as greater occipital nerve blocks; neurostimulation or electrical stimulation; occipital neurectomy; partial posterior intradural C1–C3 rhizotomy; radiofrequency ablation (thermal or pulsed) or denervation; rhizotomy of C1–C3 spinal dorsal roots; surgical decompression of second cervical nerve root and ganglion; surgical decompression of the greater occipital nerve.N/A

Explicit list from policy indicating unproven/not medically necessary interventions.

Coverage-relevant evidence summary

Summary of clinical findings relevant to coverage decisions

Evidence-supported uses: Greater occipital nerve blocks (GONB) have randomized and observational evidence demonstrating short-term pain reduction for indications including acute migraine, cluster headache, and post-dural puncture headache; many studies report improvements in pain scores and reduced headache days in the short term (hours to weeks).short-term (hours to weeks)

Meta-analyses and RCTs report short-term benefits but with heterogeneous methods and follow-up.

Comparative efficacy: Randomized trials are heterogeneous: some show GONB inferior to certain medical therapies (e.g., IV metoclopramide in ED migraine) while others show superiority to placebo or equivalence to other treatments; results vary by setting and outcome.

Findings derived from ED RCTs and multiple systematic reviews.

Limitations: Overall evidence is limited by small sample sizes, study heterogeneity, variable techniques and controls, short follow-up durations, and low-to-moderate quality; little high-quality evidence supports durable long-term benefit for chronic preventive use.

Coverage rationale and selection criteria

Coverage considerations based on available evidence and typical selection criteria in the literature

General selection: Patient selection for invasive interventions typically requires documented refractory symptoms after adequate conservative therapy and, for many procedures, a prior positive diagnostic occipital nerve block or trial indicating the targeted nerve as the pain generator.

Retrospective series and systematic reviews commonly used prior positive block responses to select patients.

Procedures with stronger short-term evidence: Greater occipital/suboccipital infiltrations (GONB) have the strongest short-term evidence particularly for cluster headache; evidence for migraine prevention is weaker and inconsistent.

AHS-IPS narrative and systematic reviews highlight short-term benefit for cluster headache.

Interventions with limited/insufficient evidence: Surgical decompression, occipital neurectomy, conventional RFA and other denervation techniques have mixed and limited evidence; long-term efficacy is not well-established and study quality is often low.

Systematic reviews and meta-analyses report limited quality and heterogeneous results.

Coverage considerations and required evidence

Evidence-based coverage considerations derived from reviewed literature

General evidence requirements: Interventional neurostimulation or radiofrequency treatments should generally be considered only after adequate trials of conservative therapies and appropriate patient selection; many studies required a positive temporary trial prior to permanent implantation.

HTA and device studies commonly required documented conservative therapy failure and positive trial response (often ≥50%).

Effectiveness evidence: Randomized controlled trial evidence exists for some noninvasive modalities (e.g., remote electrical neuromodulation) showing efficacy; evidence for invasive neurostimulation (ONS, cSCS, PNS) is variable and often low-quality, with observational series showing benefit in selected patients.

REN RCTs and multiple systematic reviews summarize mixed evidence for invasive modalities.

Device complications and follow-up: Providers should counsel patients about device- and procedure-related risks including hardware complications, infection, lead migration, need for revision or explantation, and uncertain long-term outcomes due to small study sizes.

Coverage criteria and prerequisites

Coverage considerations based on evidence and guideline recommendations

General coverage preconditions: Invasive neurostimulation (for example implanted ONS/PNS) is generally reserved for medically refractory cases after failure of conservative and pharmacologic therapies and is often performed in specialized or tertiary centers or within research protocols.

Reflects guideline emphasis on refractory status and center expertise (NICE, EHF, INS guidance).

Evidence and safety requirements: Interventions supported by higher-quality RCT evidence (such as some noninvasive neuromodulation for acute migraine) may be considered differently than invasive ONS, which has very low-quality evidence and notable complication and revision rates.

Guideline and HTA assessments distinguish noninvasive modalities with RCT support from invasive procedures with low-quality evidence.

Procedural prerequisites for RFN: Diagnostic occipital nerve block should precede occipital radiofrequency neurotomy and imaging (MRI/CT) should be used to exclude other etiologies prior to RFN.

ASPN LEARN best-practice guidance recommends diagnostic blocks and pre-procedure imaging.

Guidance-based coverage considerations

Summary of coverage-relevant clinical guidance from referenced bodies

Use within specialized context: European Headache Federation and NICE recommend that invasive neuromodulation and certain stimulation procedures be used only for medically intractable syndromes managed in tertiary/specialized centers, typically with special arrangements for governance, consent, audit, or research.

NICE and EHF emphasize governance, consent, and data collection for these procedures.

Evidence supports extracranial stimulation for specific indications: The International Neuromodulation Society (NACC) concluded evidence supports extracranial stimulation for facial pain, migraine, and scalp pain while evidence is limited for intracranial neuromodulation.

INS/NACC appraisal summarized extracranial vs intracranial evidence distinctions.

Conservative therapy precedence: NICE notes that usual migraine treatment options are medical (acute and preventive) and reserves invasive treatments (nerve blocks, botulinum toxin, interventional procedures) for patients refractory to standard therapies.

NICE guidance specifies conservative-first approach and use of invasive options in research/tertiary settings.

Occipital nerve ablation — medical necessity determination (refer to InterQual®)

Use InterQual® criteria for occipital nerve ablation medical necessity decisions

InterQual-directed criteria: Clinical coverage for occipital nerve ablation for severe cancer pain due to malignancy involving the head and neck must be determined using InterQual® CP: Procedures, Neuroablation, Percutaneous.see InterQual®

Policy removed prior assertion that neurolytic occipital nerve ablation is proven/medically necessary for cancer-related head/neck pain and now directs application of InterQual®; comply with federal/state/contractual benefit rules when applying InterQual®.

Injection of local anesthetics and/or corticosteroids as a greater occipital nerve block (GONB) is listed in the policy in the context of pain due to malignancy involving the head and neck; however, the policy now directs that coverage for occipital nerve ablation or destructive neurolytic procedures for severe cancer-related head and neck pain must be determined using InterQual® CP: Procedures, Neuroablation, Percutaneous. The prior explicit statement that neurolytic occipital nerve ablation was proven and medically necessary for malignancy-related head and neck pain has been removed and replaced with referral to InterQual criteria for medical necessity decisions.

The evidence does not support routine, long-term preventive use of GONB for chronic migraine or transformed migraine. Systematic reviews and health-technology assessments rate the overall quality of evidence as low and report only short-term benefit; there is little to no high-quality evidence demonstrating durable effectiveness for chronic preventive intent. Payers may therefore require strong justification or prior authorization for repeated or chronic preventive use of GONB and should expect documentation of prior conservative therapies and objective outcome data.

Surgical approaches for occipital neuralgia and cervicogenic headache — including occipital neurectomy and nerve decompression — have insufficient high-quality evidence to conclude long-term effectiveness. Multiple reviews conclude that randomized, well-controlled trials demonstrating durable benefit are lacking, and the policy therefore treats many surgical procedures as having uncertain long-term outcomes; prior versions asserting clear benefit for some neurolytic surgical approaches have been removed.

The body of evidence supporting routine use of neurostimulation across headache types is limited and heterogeneous. Systematic reviews and technology assessments report methodological flaws, small sample sizes, and variable results for implanted occipital nerve stimulation (ONS), cervical spinal cord stimulation (cSCS), and other invasive stimulation techniques. While some selected patients in observational series or trials show benefit, the overall evidence quality is generally characterized as very low to low, and routine coverage for broad indications is not supported without robust supporting data.

Guideline bodies advise caution in using neuromodulation outside specialized settings. The European Headache Federation and NICE recommend that invasive neurostimulation devices be used primarily for medically intractable syndromes managed in tertiary headache centers, as part of controlled studies, or with formal governance and audit arrangements. Payers and providers should consider these recommendations when evaluating requests for device-based interventions.

Botulinum toxin A is FDA-approved for certain indications but is not specifically approved for cervicogenic headache or occipital neuralgia; its use for these diagnoses is off‑label. The policy notes this regulatory context and treats botulinum toxin use for cervicogenic headache or occipital neuralgia as outside labeled indications, requiring clinical justification if considered.

The policy removed prior language that explicitly stated occipital nerve ablation by a neurolytic agent was proven and medically necessary for malignancy-related head and neck pain. That assertion has been replaced by a directive to apply InterQual® criteria for neuroablation medical necessity determinations.

The policy lists several procedures as unproven or not medically necessary for occipital neuralgia and headaches, including neurostimulation/electrical stimulation, occipital neurectomy, partial posterior intradural C1–C3 rhizotomy, radiofrequency ablation (thermal or pulsed) or denervation, rhizotomy of C1–C3 dorsal roots, and surgical decompression of the second cervical nerve root/ganglion or the greater occipital nerve.

Randomized controlled trials and meta-analyses have not consistently demonstrated that GONB is superior to placebo for reducing moderate‑to‑severe migraine frequency. Some RCTs report no difference versus placebo, and health-technology assessments conclude the evidence for preventive, long-term benefit is low and inconsistent.

Several surgical procedures — including occipital neurectomy and nerve decompression techniques — lack reliable long-term effectiveness data. Systematic reviews emphasize limited study quality and heterogeneity; reported short-term improvements in some retrospective series have not been confirmed in well‑designed trials with long-term follow-up.

Evidence for radiofrequency neurotomy, continuous RFA, and pulsed RFA in cervicogenic headache is limited and inconsistent. Systematic reviews and randomized trials show mixed results, with some studies reporting benefit and others showing no significant advantage; overall the literature is insufficient to establish consistent long‑term effectiveness.

Invasive occipital nerve stimulation (ONS) for chronic cluster headache or chronic migraine has shown variable benefit in small studies and carries substantial complication and revision rates. Given the very low‑quality evidence and reported hardware‑related adverse events, the policy indicates such invasive ONS approaches may be considered not medically necessary when used outside well‑designed clinical studies or tertiary‑center protocols.

Aside from the removal of the prior proven/medically necessary assertion for neurolytic occipital nerve ablation in cancer‑related pain, this policy fragment does not add broad new explicit 'not medically necessary' statements beyond the listed unproven procedures; determinations for neuroablation in cancer pain are now governed by InterQual® criteria.

Coding

Applicable CPT CodesCPT

63185	Laminectomy with rhizotomy; 1 or 2 segments.
63190	Laminectomy with rhizotomy; more than 2 segments.
64405	Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve.
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve.
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64568	Open implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
64570	Removal of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
64575	Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.

1–10 of 18

1/2

Applicable HCPCS CodesHCPCS

A4540	Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm.
L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.

Applicable ICD-10 Codes (examples)ICD-10

C76.0	Malignant neoplasm of head, face and neck.
G89.3	Neoplasm related pain (acute) (chronic).

Codes referenced in this sectionmixed

No codes listed

Codes mentioned in this sectionmixed

No codes listed

RFA device product codes (FDA)mixed

GXD	FDA product code for radiofrequency lesion generators
GXI	FDA product code for radiofrequency lesion probes

Electrical stimulation device product codes (FDA)mixed

GZF	FDA product code for electrical stimulation devices (example group)
GZB	FDA product code for electrical stimulation devices (example group)
PCC	FDA product code for electrical stimulation devices (example group)

Removed HCPCS CodesHCPCSNot Covered

K1023

HCPCS code (removed from policy)

Responder definition in trials — ≥50% reduction

Responder threshold used in many trialsDefined as >=50% reduction in headache days or pain (commonly used to designate treatment response)

Context of useApplied in randomized and observational studies to define responder status for neuromodulation and neuromodulatory devices

Reported endpointsOften reported as proportion of participants achieving >=50% reduction at specified follow-up (examples: REN trial reported percent achieving 50% reduction)

InterQual criteria reference

Referenced proprietary criteria

Provider Actions and Authorization Guidance

Documentation Required

Temporary trial and documentation recommended

Recommend a temporary neuromodulation trial and document objective response prior to permanent implantation. A temporary trial (commonly ≥50% pain reduction, or as specified by device-specific or specialty guidance) should be performed and documented (trial duration, pain scores, functional improvement, and adverse events) to support selection for permanent occipital or supraorbital neurostimulator implantation.

Document baseline headache frequency, severity, prior treatments, and objective trial response (e.g., VAS/NRS scores, headache days per month).
Record trial start/stop dates, stimulation parameters, and any complications or lead issues.

Prior Authorization

Prior authorization for neuromodulation

Prior authorization is recommended/required for implantation and many neuromodulation procedures. Coverage decisions for neurostimulation and percutaneous neuroablation may follow InterQual® criteria or UnitedHealthcare prior authorization processes; submit clinical notes documenting prior conservative therapy, diagnostic block responses, and trial outcomes.

Conservative Treatment Requirements

Consideration of pharmacologic conservative therapy prior to invasive procedures implied in background discussion

Conservative pharmacologic therapy and guideline-directed acute interventions are generally expected prior to invasive procedures where applicable

Consideration of conservative pharmacologic therapy: Oral analgesics and anti-inflammatory agents are effective for many patients and should be considered as initial therapy prior to invasive interventions for occipital-related head pain.

Policy background describes medications as first-line options before invasive treatments.

Trial of guideline-directed acute ED therapies before procedural intervention: For acute migraine presenting to the ED, a trial of guideline-directed medical therapies (for example IV metoclopramide or NSAIDs) is reasonable prior to performing a GONB, given RCT data showing some comparators may be superior.

ED RCTs compared GONB with IV metoclopramide and found variable comparative efficacy.

Documented failure prior to escalation:

Frequency Limits and Re-intervention

GONB — frequency guidance

Frequency limit statementNo explicit frequency limit for GONB is provided in this policy section

Evidence contextGONB evidence shows short-term benefit in multiple RCTs and meta-analyses but little evidence supports routine chronic preventive use

Documentation implicationProviders should document indication, prior conservative therapies, and response; frequency/repeat use may require justification given limited long-term evidence

C2 DRG pulsed RFA and other RFA — frequency guidance

Frequency limit statementNo explicit frequency limits stated for C2 DRG pulsed RFA or other RFA procedures in this section; literature reports single procedures with variable duration of relief

Reported durability

Imaging and Procedural Guidance

Billing Rule

Document imaging when performing percutaneous electrode array insertion (CPT 64596/64597)

CPT 64596/64597 (percutaneous electrode array insertion) include imaging guidance when performed; document imaging use on claims and in clinical records.

Include imaging guidance details when performed (per CPT description).
Listing of codes is for reference and does not guarantee coverage.

Documentation Required

Imaging for GONB is optional — document if used

Ultrasound guidance has been used in trials to locate the greater occipital nerve and is described as optional; document if ultrasound guidance was used.

Ultrasound‑guided GONB was used in small trials.
Imaging for GONB is optional per policy text.

Not Covered / Experimental Procedures

The following interventions are listed in the policy inventory as not covered or unproven and are presented here for operational clarity: neurostimulation/electrical stimulation, occipital neurectomy, partial posterior intradural C1–C3 rhizotomy, radiofrequency ablation (thermal or pulsed) or denervation, rhizotomy of C1–C3 dorsal roots, and surgical decompression of the greater occipital nerve or second cervical root/ganglion.

Duplicate inventory entry retained per planning instructions; content mirrors the listed unproven/not medically necessary procedures above.

Background and Definitions

Cervicogenic headache and occipital neuralgia are described as head pain syndromes arising from the neck and upper cervical nerve roots, often attributed to compression, entrapment, or dysfunction of occipital nerves or C2–C3 roots. Clinical presentations commonly include unilateral or bilateral head and neck pain, sometimes radiating to the shoulder or arm, and management options range from conservative medical therapy to injections, radiofrequency techniques, neurostimulation, and surgery—though the quality and durability of evidence varies by intervention.

Cervicogenic Headache — definition

DefinitionCervicogenic headache: Referred pain perceived in the head from a source in the neck; caused by disorder of the cervical spine and related structures

Clinical attributionSymptoms attributed to compression or pathology of upper cervical spinal elements leading to head/neck pain

Source referenceTerm defined per American Migraine Foundation (policy definitions section)

Neurectomy — definition

Revision History

2024-11-01removed_language

Removed language stating occipital nerve ablation by neurolytic agent is proven and medically necessary for treating pain due to malignancy involving the head and neck.

2024-11-01revised_instruction

Updated policy to direct use of InterQual® CP: Procedures, Neuroablation, Percutaneous for medical necessity determinations for occipital nerve ablation in severe cancer-related head and neck pain.

2024-11-01code_removed

Policy Summary

PayerUnitedHealthcare

PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for Kentucky Only)

Policy CodePolicy CS086KY.11

Change TypeMaterial revisions and code removal

Effective DateNov 1, 2024

Next Review Date

Key ActionUse InterQual CP: Procedures, Neuroablation, Percutaneous to determine medical necessity for occipital nerve ablation in severe cancer-related head and neck pain.

SourceLink

On This Page

Multiple systematic reviews and HTA assessments note low or limited quality evidence.

RFA considerations: Radiofrequency ablation (continuous or pulsed) may provide meaningful pain reduction for some patients, but outcomes are variable and long-term (>1 year) benefit is under-studied; diagnostic blocks and careful selection are frequently used prior to RFA.

Supported by retrospective analyses and systematic reviews noting variable outcomes and need for further study.

Systematic reviews and series report substantial rates of adverse events and revisions for implanted neuromodulation.

Device and procedural safety note: Devices used for electrical stimulation and RFA are regulated via FDA 510(k) (example product codes include GZF, GZB, PCC for stimulation and GXD/GXI for RFA devices); RFA as a procedure is not itself FDA-regulated.

FDA device/regulatory context provided in policy for informational purposes.

InterQual® CP: Procedures, Neuroablation, Percutaneous — used for medical necessity determinations for occipital nerve ablation

Policy directivePolicy instructs that occipital nerve ablation for severe cancer pain due to head/neck malignancy must be determined using InterQual criteria

Operational noteWhen InterQual does not have applicable criteria, UnitedHealthcare may use other approved medical policies or guidelines; follow federal/state/contractual rules

Refer to InterQual® CP: Procedures, Neuroablation, Percutaneous for occipital nerve ablation for severe cancer pain.
Prior authorization may be required for permanent ONS/SON implantation and for ablation procedures—check payer-specific rules before scheduling.

Denial Risk

Denial for unproven interventions

Procedures and devices lacking sufficient evidence may be denied as not medically necessary. Interventions identified in evidence reviews or the policy as unproven should be expected to have a higher denial risk when used for indications without supportive high‑quality evidence.

Examples of procedures at risk for denial when used outside accepted criteria: some neurostimulation applications, occipital neurectomy, certain rhizotomies, and RF ablation for unproven indications.
Chronic preventive/off‑label chronic use without evidence of long‑term benefit may be denied.

Denial Risk

Denial risk for chronic preventive use

Long‑term preventive (chronic) use of some interventional therapies (e.g., repeated GONB, chronic neuromodulation without documented sustained benefit) may lack sufficient evidence of durable benefit and carries a higher risk of denial. Document rationale and prior evidence of sustained benefit when requesting authorization for chronic preventive indications.

For GONB, evidence supports short‑term benefit but shows little/no evidence for chronic preventive use—include trial data and objective outcomes if requesting coverage for repeated or chronic use.
If requesting chronic neuromodulation coverage, provide long‑term follow‑up demonstrating sustained ≥50% benefit where available.

Denial Risk

Evidence‑related denial risk

Limited, low‑quality, or heterogeneous evidence across studies increases the risk that a procedure will be considered not medically necessary. When evidence is insufficient (small sample sizes, observational designs, inconsistent outcomes), expect closer scrutiny and potential denial.

Radiofrequency ablation and many neurostimulation indications have mixed/low‑quality evidence—provide high‑quality supporting documentation if requesting coverage.
Retrospective series or uncontrolled studies alone are often inadequate to establish medical necessity for coverage.

Denial Risk

Insufficient evidence may trigger denial

Insufficient or low‑quality evidence may trigger denial decisions. Requests supported only by case series, small retrospective cohorts, or studies with high risk of bias should include additional objective clinical rationale and, where applicable, a plan for monitoring outcomes.

If relying on observational data, include detailed justification, prior conservative treatment failures, and documented diagnostic block or trial responses.
Consider referring patients to centers participating in clinical research when evidence is lacking.

Documentation Required

Governance/audit requirements for certain neuromodulation procedures

Where guidance (e.g., NICE) recommends special arrangements, clinicians must follow governance and audit processes when offering certain neuromodulation procedures. Ensure informed consent discusses uncertainties, and maintain outcome audit data per guidance.

For transcutaneous supraorbital nerve (SON) stimulation used acutely: document clinical governance approvals, consent discussions, and plan for audit/reporting of outcomes.
Collect and retain outcome measures (headache days, pain scores, medication use) and adverse events for review.

Prior Authorization

InterQual referral for neuroablation

For occipital nerve ablation for severe cancer‑related head and neck pain, coverage determinations should follow InterQual® percutaneous neuroablation criteria. Use InterQual® as the primary clinical criteria reference when applicable.

If InterQual® criteria apply, include the InterQual® determination reference in the prior authorization submission.
For cancer‑related severe pain, ensure documentation of cancer diagnosis, prior systemic/medical pain management, and palliative intent.

Billing Rule

Coding and clinical documentation

Submit complete coding and supporting clinical documentation. Include all relevant procedure codes, diagnosis codes, and modifiers, and ensure clinical notes reference the codes and rationale for the procedure.

Include CPT/HCPCS codes for the planned procedure(s) and any associated device or lead implantation codes.
If codes were removed or updated (e.g., HCPCS K1023 removed per policy history), use current applicable codes and document the change.

Documentation Required

Prior response and conservative therapy documentation

Document prior conservative therapy attempts and the individual's response to diagnostic nerve blocks and other noninvasive treatments. Provide dates, medication names/doses, duration of trials, and reasons for discontinuation or failure.

Describe trials of guideline‑directed medical therapy (e.g., acute migraine treatments in ED) and outcomes before escalating to procedural interventions.
Include imaging or other studies used to rule out secondary causes when applicable.

Documentation Required

Trial response and selection documentation

Document objective trial response and selection criteria for permanent procedures. For neurostimulation, record trial thresholds used to define a responder (commonly ≥30% or ≥50% improvement) and provide the measured outcome data used to select patients for implantation.

Specify the responder threshold applied (e.g., ≥50% pain reduction) and the metric used (VAS/NRS, headache days/month).
Include trial duration, stimulation settings, and any adverse events that occurred during the trial.

Documentation Required

Documentation and audit for transcutaneous SON stimulation

When offering transcutaneous supraorbital nerve (SON) stimulation (or other procedures with NICE conditional recommendations), document governance arrangements, obtain informed consent that highlights uncertainties, and maintain an outcomes audit for all patients.

Provide written patient information on the procedure's expected benefits, risks, and evidence limitations.
Submit audit data into local governance systems and retain for periodic review and quality improvement.

Documentation Required

Documentation & plan applicability

Ensure documentation references applicable benefit plan terms and the use of InterQual® or other designated criteria. In case of conflict, federal, state, or contractual requirements govern coverage decisions.

State which clinical criteria were used (InterQual®, specialty guidelines) in the authorization request.
Confirm that the requested service aligns with the member's federal/state/contractual benefit plan requirements.

Step Therapy

Conservative therapy context

Conservative treatments (oral analgesics, antiinflammatory agents, behavioral therapies) are effective for many patients and are generally preferred first‑line. Document attempts and failures of conservative management before requesting more invasive procedures.

Include dates and outcomes of pharmacologic, behavioral, and less‑invasive interventional therapies tried.
If escalation is requested from ED acute treatment, document that guideline‑directed acute therapies were attempted per step‑therapy considerations.

Step Therapy

Step therapy considerations

Consider stepwise care: trial guideline‑directed acute medical therapy (especially in ED settings) before procedural interventions, and document the sequence of treatments. Escalation to nerve blocks or procedures is appropriate when conservative measures fail.

For ED migraine presentations, document that first‑line IV or oral therapies were attempted prior to GONB when applicable.
Record rationale for proceeding to nerve block or ablation (e.g., refractory pain, contraindications to medications).

Step Therapy

Stepwise escalation

Escalate care stepwise: begin with conservative therapies, progress to diagnostic nerve blocks, then consider longer‑lasting interventions (e.g., RFN, neurostimulation, decompression) for appropriately selected, refractory patients. Provide documentation of each step and the clinical reasoning for escalation.

Diagnostic nerve blocks should generally precede radiofrequency neurotomy and other ablative procedures.
For surgical or implantable device options, document multidisciplinary evaluation and prior treatment failures.

Step Therapy

Conservative therapy before invasive neuromodulation

Exhaust guideline‑directed pharmacologic and noninvasive preventive options before invasive neuromodulation. Neuromodulation is generally considered for medically refractory cases after adequate trials of established therapies.

Document duration and adequacy of preventive medication trials (doses, adherence, tolerability) and nonpharmacologic therapies.
Include specialty consultation notes (e.g., headache specialist, neurosurgery) when applicable to support the decision for invasive neuromodulation.

Documented failure of appropriate conservative and pharmacologic therapies should be recorded before escalating care to ablation, neurostimulation, or surgery.

Multiple reviews and studies required prior conservative therapy failure as inclusion criteria for interventional procedures.

Trial of guideline-directed acute medical therapy prior to procedural intervention for acute migraine in ED settings

When treating acute migraine in emergency settings, guideline-directed medical therapy should generally be tried before procedural interventions

ED acute migraine management prior to GONB: In emergency department management of moderate-to-severe migraine, consider guideline-directed acute medical therapies (e.g., IV metoclopramide, NSAIDs) as first-line; GONB may be considered if medical therapy is ineffective or contraindicated.

Friedman et al. and other ED RCTs provide comparative data showing variable efficacy of GONB versus IV therapies.

Document failure of appropriate conservative therapies before escalating to ablation or surgery

Requirement to document conservative therapy failure: Prior to considering ablation or surgical decompression/neurectomy, clinical records should document trials and inadequate response to appropriate conservative therapies (pharmacologic and noninvasive interventions) and any diagnostic block responses.

Retrospective reviews and systematic analyses commonly used prior conservative therapy failure as an inclusion criterion for surgical/interventional studies.

Documented failure of conservative treatments expected before considering interventional/device therapies

Documented failure of conservative treatments is expected before considering interventional/device therapies

Expectation of documented failure: Studies of pulsed RFA, radiofrequency ablation, and neurostimulation typically enrolled patients who had failed conservative therapy; documentation of such failure should be included when requesting coverage for interventional/device therapies.

Evidence summaries and HTA reports indicate prior conservative therapy failure as standard in study inclusion and device selection.

Failure or intolerance of standard therapies prior to invasive neurostimulation

Failure or intolerance of standard therapies is expected prior to invasive neuromodulation

Conservative therapy before neuromodulation: Guidelines and systematic reviews generally recommend that invasive neuromodulation (such as implanted ONS or cervical SCS) be reserved for patients who have failed or are intolerant of standard pharmacologic and other established preventive therapies.

NICE, VA/DoD, and HTA guidance emphasize exhaustion of standard therapies prior to invasive neuromodulation.

Temporary trial requirement for permanent implantation: Permanent implantation of occipital neurostimulation devices is typically preceded by a positive temporary trial (commonly defined in studies as ≥50% reduction in pain/headache frequency); documentation of trial outcome is expected.>=50% reduction (commonly used in trials)

Hayes HTA and multiple device studies described trial-based selection with responder thresholds (often ≥50%).

Trial of standard medical therapies prior to invasive neuromodulation or interventional procedures per NICE guidance

NICE guidance emphasizes a stepwise trial of standard medical therapies before invasive neuromodulation or interventional procedures

NICE-directed trial of standard therapies: Per NICE, usual migraine treatment options are medical (acute and preventive agents); invasive treatments including nerve blocks and other interventional procedures should be reserved for patients refractory to standard therapies and, for some procedures, used only with governance/audit arrangements or in research contexts.

NICE specifically recommends governance, consent, audit, and research frameworks for certain procedures and that preventive use be considered investigational without adequate evidence.

Studies report variable duration of benefit (examples: mean duration ~254 days reported for occipital RFA retrospective series)

Selection criteriaPatient selection often based on prior positive diagnostic block predicting response to RFA/PRF

Pulsed radiofrequency / RFA — frequency guidance

Frequency limit statementPolicy does not specify explicit repeat/procedure frequency for pulsed radiofrequency (PRF) or RFA

Effectiveness evidenceSome prospective and retrospective studies report sustained benefit after single PRF treatments, but high-quality evidence is limited

RecommendationRepeat treatments and long-term scheduling should be justified by clinical response and documentation due to limited robust long-term data

Occipital PNS/ONS follow-up and re-intervention frequency

Frequency limit statementFollow-up and need for re-intervention after occipital PNS/ONS are not standardized; studies report variable revision and battery-replacement rates

Complication and revision dataONS series report substantial rates of complications and revisions (examples: infection and device-related revisions up to reported ranges), necessitating individualized follow-up planning

Clinical implicationDecisions about re-intervention, battery replacement, or revision should be based on device performance, patient response, and documented need rather than preset frequency limits

Sphenopalatine ganglion stimulation — NICE guidance

NICE recommendationImplantation of sphenopalatine ganglion stimulation should be used only with special arrangements for clinical governance, consent, and audit or research

Evidence statusNICE judged short-term evidence adequate but recommends use only within governance/research settings and encourages further research

Provider implicationImplantation should occur in settings with oversight, data collection, and informed-consent processes acknowledging uncertainties

Occipital nerve procedures when InterQual specifies frequency limits

InterQual-governed frequency limitsWhen InterQual® criteria apply to occipital nerve procedures, frequency and appropriateness should be determined per InterQual guidance rather than by preset policy limits

Operational changePolicy removed prior assertion of neurolytic ablation as universally proven for cancer-related head/neck pain and now directs use of InterQual for neuroablation decisions

Authorization implicationFailure to document InterQual-specified criteria may lead to denial for occipital nerve procedures when InterQual applies

Billing Rule

Use and document fluoroscopy/CT for C2 DRG block and PRFT

Fluoroscopy or CT guidance is commonly used for C2 DRG block and for pulsed radiofrequency treatment of the sphenopalatine ganglion; document imaging modality used.

Some studies performed fluoroscopy‑guided C2 DRG block prior to PRFT.
CT guidance described for PRFT of sphenopalatine ganglion.

Documentation Required

Document image guidance for PRFT/RFA procedures

Pulsed radiofrequency and conventional RFA procedures are often performed with CT or ultrasound guidance for target localization; document imaging guidance on procedure reports.

CT/ultrasound guidance commonly described for PRFT/RFA in the literature.
Document imaging and technique to support medical necessity.

Documentation Required

Require diagnostic block and MRI/CT before occipital RFN

Diagnostic blockade of the occipital nerves should precede occipital radiofrequency neurotomy and MRI/CT is recommended to rule out other etiologies before RFN; document diagnostic block and imaging findings.

ASPN best practices recommend diagnostic block before RFN.
Obtain MRI/CT to exclude other causes prior to neurotomy.

Documentation Required

Obtain neuroimaging when indicated for initial cluster headache evaluation

For initial evaluation of cluster headache, neuroimaging is recommended when indicated; document imaging decisions per guidance.

NICE recommends discussing neuroimaging for first bout of cluster headache with a specialist.
Document whether neuroimaging was performed and the indication.

Documentation Required

Follow InterQual®/UnitedHealthcare policy for imaging and documentation requirements

Follow InterQual® or applicable UnitedHealthcare policies for any required imaging guidance or documentation when requesting coverage or submitting claims for occipital procedures.

InterQual® may specify additional imaging or documentation requirements for neuroablation.
Plan/federal/state contractual rules govern coverage determinations.

Routine use of GONB for chronic preventive management is not supported by convincing long‑term evidence. The policy lists routine chronic preventive GONB as not covered or requiring substantial justification because systematic assessments rate the evidence as low and note little data supporting durable preventive benefit.

Duplicate inventory entry retained per planning instructions; content mirrors the listed unproven/not medically necessary procedures above.

Invasive occipital nerve stimulation for indications lacking sufficient evidence—such as chronic cluster headache or other refractory syndromes—may be considered not covered or experimental when performed outside of well‑designed clinical trials or specialized tertiary‑center programs, due to limited RCT data and high complication/revision rates reported in observational series.

Duplicate inventory entry retained per planning instructions; content mirrors the listed unproven/not medically necessary procedures above.

The policy no longer contains the prior assertion that occipital nerve ablation by a neurolytic agent is proven and medically necessary for treating pain due to malignancy involving the head and neck; that language was removed and InterQual® criteria are now referenced for neuroablation coverage decisions.

DefinitionNeurectomy: Partial or total excision or resection of a nerve

Procedural implicationSurgical removal of nerve tissue intended to interrupt pain signaling; considered unproven for occipital neuralgia in this policy

Source referenceDefinition from Taber's Medical Dictionary as cited in policy definitions

Rhizotomy — definition

DefinitionRhizotomy: Surgical section of a nerve root to relieve pain

Procedural implicationSurgical interruption of dorsal root fibers (e.g., C1-C3) described in policy as having insufficient evidence for occipital-related headaches

Source referenceDefinition from Taber's Medical Dictionary as cited in policy definitions

GONB — definition

DefinitionGONB: Injection of local anesthetic (with or without corticosteroid) around the greater occipital nerve intended to provide diagnostic information and short-term symptomatic relief for head pain

Clinical useUsed diagnostically and therapeutically for occipital-related headaches; evidence supports short-term benefit in multiple studies and meta-analyses

Typical agentsLocal anesthetics (e.g., lidocaine, bupivacaine) with or without corticosteroid as reported in trials

ONS — definition

DefinitionONS: Occipital nerve stimulation — implanted peripheral nerve stimulation targeting occipital nerves to reduce headache frequency/intensity, often preceded by a temporary trial

Clinical considerationsImplantation studies commonly require a positive temporary trial; invasive ONS associated with notable complication and revision rates in reviews

Evidence statusEvidence for ONS is mixed and of low to very low quality for many indications; used for refractory cases in specialized centers

Greater Occipital Nerve Block (GONB) — definition

DefinitionGreater Occipital Nerve Block (GONB): Injection targeting the greater occipital nerve with local anesthetic, often with or without corticosteroid, used diagnostically and therapeutically for occipital/occipital-related headaches

PurposeProvides short-term pain relief and diagnostic information to help identify occipital nerve-mediated pain

Evidence noteMultiple RCTs and meta-analyses report short-term reductions in headache days and pain scores

Radiofrequency Ablation (RFA) — definition

DefinitionRadiofrequency Ablation (RFA): Ablative or pulsed radiofrequency procedure applied to occipital nerves or C2 dorsal root ganglion intended to provide longer-term pain relief through lesioning or neuromodulation

ModalitiesIncludes continuous thermal RFA (lesioning) and pulsed radiofrequency (non-ablative neuromodulation)

Regulatory noteProcedure itself is not FDA-regulated though devices used are regulated via FDA 510(k) product codes

Pulsed radiofrequency (PRF/PRFT) — definition

DefinitionPulsed radiofrequency (PRF/PRFT): A non-ablative radiofrequency technique delivering intermittent high-voltage pulses intended to modulate neural function without thermal lesioning

Clinical useStudied for neuralgias and some headache syndromes; evidence reports variable effectiveness and limited high-quality data

Outcome measuresEffectiveness often reported as proportion achieving >50% pain reduction at follow-up intervals

Occipital nerve stimulation (ONS) — definition

DefinitionOccipital nerve stimulation (ONS): An implanted peripheral nerve stimulation approach targeting occipital nerves to reduce headache frequency/intensity, often preceded by a temporary trial

Typical pathwayTemporary trial commonly used to select responders prior to permanent implantation

Safety considerationsONS associated with device-related complications including infection, lead issues, and revision/explantation in reported series

Remote Electrical Neuromodulation (REN) — definition

DefinitionRemote Electrical Neuromodulation (REN): A noninvasive, device-delivered electrical stimulation used for migraine prevention/acute treatment, studied in randomized controlled trials

Evidence exampleA multicenter RCT (Tepper et al.) with 248 participants demonstrated REN superiority vs placebo for reducing migraine days and percent achieving 50% reduction

Regulatory statusDevices such as Nerivio have received FDA De Novo/clearance for acute and later chronic migraine indications

Occipital Nerve Stimulation (ONS) — definition (duplicate)

Definition (duplicate)Occipital Nerve Stimulation (ONS): Implanted peripheral neurostimulation targeting occipital nerves to reduce headache frequency/intensity; often preceded by a temporary trial

Evidence noteSee ONS evidence summaries and safety concerns; duplicate entry retained for cross-reference

Clinical implicationConsider trial response documentation and prior conservative therapy before permanent implantation

Transcutaneous / Noninvasive Stimulation — definition

DefinitionTranscutaneous/Noninvasive Stimulation (tONS, eTNS, TENS, REN): Noninvasive electrical stimulation modalities applied externally (e.g., Cefaly device, transcutaneous occipital nerve stimulation) used for acute or preventive migraine treatment

Modalities includedExamples: external trigeminal nerve stimulation (eTNS), transcutaneous occipital nerve stimulation (tONS), TENS, and REN

Guidance noteNICE reviewed eTNS and provided specifics on application, duration, and governance for use in migraine

eTNS / supraorbital stimulation — definition

DefinitionTranscutaneous electrical stimulation of the supraorbital nerve (eTNS/external trigeminal nerve stimulation): Noninvasive stimulation via skin-applied electrode to supraorbital branches to relieve acute headache and potentially reduce migraine frequency when used regularly

Device useTypically self-administered via headband with adhesive electrode; applied daily for acute or preventive protocols per NICE guidance

Safety considerationsKey safety outcomes include pain, weakness, poststimulation headaches, and potential worsening of migraine as discussed by NICE

RFA — device/regulatory definition

Regulatory/device definitionRadiofrequency ablation (RFA): Procedure that uses radiofrequency energy to create lesions for nerve ablation; the procedure itself is not FDA-regulated though devices used are regulated via FDA 510(k) product codes (e.g., GXD, GXI)

Device codingFDA product codes for RFA devices include GXD (lesion generators) and GXI (lesion probes)

ImplicationDevice regulatory status is informational and does not by itself establish coverage or medical necessity

InterQual® — definition/description

DefinitionInterQual®: A proprietary clinical criteria set used by UnitedHealthcare for medical necessity determinations (used here for neuroablation decisions)

Policy useUnitedHealthcare uses InterQual for primary medical/surgical criteria; when applicable, InterQual criteria govern coverage decisions for neuroablation

Operational noteIf InterQual lacks applicable criteria, UnitedHealthcare may use other approved medical policies or guidelines per plan rules

Removed HCPCS code K1023 from the policy's applicable codes.